Top

Published in:

01-09-2013 | Original Article

Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

Authors: Masanori Kobayashi, Tomoyo Sakabe, Hirofumi Abe, Mitsugu Tanii, Hidenori Takahashi, Asako Chiba, Eri Yanagida, Yuta Shibamoto, Masahiro Ogasawara, Shun-ichi Tsujitani, Shigeo Koido, Kazuhiro Nagai, Shigetaka Shimodaira, Masato Okamoto, Yoshikazu Yonemitsu, Noboru Suzuki, Masaki Nagaya, The DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)

Published in: Journal of Gastrointestinal Surgery | Issue 9/2013

Abstract

Background

The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs).

Methods

Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined.

Results

No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively (P = 0.023).

Conclusions

Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.

Available only for authorised users

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRef

Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008;13:415–23.PubMedCrossRef

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.PubMedCrossRef

Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.PubMedCrossRef

Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA, Yamashita N. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res. 2003;13:521–30.PubMedCrossRef

Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41:195–205.PubMedCrossRef

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med. 2010;363:411–22.PubMedCrossRef

Kuwabara K, Nishishita T, Morishita M, Oyaizu N, Yamashita S, Yamashita N, et al. Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer. Thyroid. 2007;17:53–8.PubMedCrossRef

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–37.PubMedCrossRef

10.

Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804–14.PubMed

11.

Ghosh M, Kamma H, Kawamoto T, Koike N, Miwa M, Kapoor VK, Krishnani N, Agrawal S, Ohkohchi N, Todoroki T. MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol. 2005;31:891–6.PubMedCrossRef

12.

Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep. 2009;22:649–57.PubMedCrossRef

13.

Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004; 122:61–9.PubMedCrossRef

14.

Fan XN, Karsten U, Goletz S, Cao Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol Res Pract. 2010;206:585–9.PubMedCrossRef

15.

Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer. 2002;94:1770–6.PubMedCrossRef

16.

Onodera T, Goseki N, Nosaki G. Prognostic nutritional index in gastro-intestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85:1001–5.PubMed

17.

Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2011;2:95–101.PubMed

18.

Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006;57:647–53.PubMedCrossRef

19.

Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6:955–64.PubMed

20.

Shimizu K, Kotera Y, Aruga A, Takeshita N, Takasaki K, Yamamoto M. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2012;19:171–8.PubMedCrossRef

21.

Berger TG, Schultz ES. Dendritic cell-based immunotherapy. Curr Top Microbiol Immunol. 2003;276:163–97.PubMedCrossRef

22.

Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 2003;21:873–86.PubMedCrossRef

23.

Hoos A, Eggermont AMM, Janetzki A, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved Endpoints for Cancer Immunotherapy Trials. J Natl Cancer Inst. 2010;102:1388–97.PubMedCrossRef

24.

Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105:3005–10.PubMedCrossRef

25.

Heys SD, Walker LG, Deehan DJ, Eremin OE. Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb. 1998;43:163–8.PubMed

26.

Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Chung IJ. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer. 2011;14:249–56.PubMedCrossRef

27.

Ramacciato G, Corigliano N, Mercantini P, Di Benedetto F, Masetti M, Ercolani G, Lauro A, De Ruvo N, Pinna AD. Prognostic factors after surgical resection for hilar cholangiocarcinoma. Ann Chir. 2006;131:379–85.PubMedCrossRef

28.

Medina-Franco H, Ramos-Gallardo G, Orozco-Zepeda H, Mercado-Díaz MA. Prognostic factor in gallbladder cancer. Rev Invest Clin. 2005;57:662–5.PubMed

29.

Fukushima K, Ueno Y, Kawagishi N, Kondo Y, Inoue J, Kakazu E, Ninomiya M, Wakui Y, Saito N, Satomi S, Shimosegawa T. The nutritional index ‘COUNT’ is useful for predicting long-term prognosis of patients with end-stage liver disease. Tohoku J Exp Med. 2011;224:215–9.PubMedCrossRef

30.

Okada I, Shirahata A, Soda H, Saitou M, Kigawa G, Nemoto H, Sanada Y, Hibi K. Significance of Onodera's prognostic nutritional index for treating unresectable or recurrent colorectal cancer with chemotherapy. Gan To Kagaku Ryoho. 2012;39:231–5.PubMed

31.

Kang Sh, Cho KH, Park JW, Yoon KW, Do JY. Onodera's Prognostic Nutritional Index as a Risk Factor for Mortality in Peritoneal Dialysis Patients. J Korean Med Sci. 2012;27:1354–8.PubMedCrossRef

32.

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028–30.PubMedCrossRef

33.

Luo Y, Dorf ME. Delayed-type hypersensitivity. Curr Protoc Immunol. 2001; Chapter 4: Unit 4.5.pp1-5.

Title: Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer
Authors: Masanori Kobayashi
Tomoyo Sakabe
Hirofumi Abe
Mitsugu Tanii
Hidenori Takahashi
Asako Chiba
Eri Yanagida
Yuta Shibamoto
Masahiro Ogasawara
Shun-ichi Tsujitani
Shigeo Koido
Kazuhiro Nagai
Shigetaka Shimodaira
Masato Okamoto
Yoshikazu Yonemitsu
Noboru Suzuki
Masaki Nagaya
The DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)
Publication date: 01-09-2013
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 9/2013
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-013-2286-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2013

What is the Best Primary Therapy for Achalasia: Medical or Surgical Treatment? Who Owns Achalasia?

Evidence-Based Management of Colorectal Trauma

Influence of Age on Clinical Outcome of Acute Diverticulitis

Effect of Donor Right Hepatectomy on Splenic Volume and Platelet Count for Living Donor Liver Transplantation

Extent of Lymphadenectomy Does Not Predict Survival in Patients Treated with Primary Esophagectomy

Patterns of Consultation and Treatment of Patients with Hepatocellular Carcinoma Presenting to a Large Academic Medical Center in the US